Reply to Agrawal and Kumar
Clin Infect Dis
.
2021 Aug 2;73(3):e846.
doi: 10.1093/cid/ciaa1507.
Authors
Kevinkumar Kansagra
1
,
Deven Parmar
2
,
Sanjeev Kumar Mendiratta
3
,
Jatin Patel
1
,
Shuchi Joshi
1
,
Nitin Sharma
1
,
Anurag Parihar
1
,
Swapnil Bhoge
1
,
Harilal Patel
4
,
Pankaj Kalita
5
,
Renuka Munshi
6
,
Prakash Kurmi
7
,
Ruchir Shah
8
,
Abhishek Gupta
9
,
Hira Lal Bhalla
9
,
Harish Bekkalele
10
,
Rajendra Kumar Verma
11
,
Dinesh Agarwal
12
,
Shrikant Sharma
13
,
Avinash Gawande
14
,
Gaurav Chhaya
15
Affiliations
1
Clinical R&D, Cadila Healthcare Limited, Ahmedabad, India.
2
Zydus Discovery DMCC, Dubai, United Arab Emirates.
3
Biologics R&D and Mfg, Cadila Healthcare Limited, Ahmedabad, India.
4
Drug Metabolism and Pharmacokinetic, Cadila Healthcare Limited, Ahmedabad, India.
5
Biotechnology, Cadila Healthcare Limited, Ahmedabad, India.
6
TN Medical College and BYL Nair Charitable Hospital, Mumbai, India.
7
Shivam Hospital, Ahmedabad, India.
8
Medistar Hospital, Himatnagar, India.
9
Subharti Medical College, Meerut, India.
10
Mandya Institute of Medical Science, Mandya, India.
11
GSVM Medical College, Kanpur, India.
12
Marwari Hospital and Research Centre, Guwahati, India.
13
SMS Medical College, Jaipur, India.
14
Government Medical College, Nagpur, India.
15
Saviour Hospital, Ahmedabad, India.
PMID:
33011769
DOI:
10.1093/cid/ciaa1507
No abstract available
Publication types
Letter
Comment